Features
Through the call for proposals Pre-clinical Therapeutics Pipeline Program 2025-3 , the development of therapies with clear potential to prevent, halt, or slow the progression of Parkinson’s disease or to reduce the burden of daily symptoms.
Specifically, through the “Pre-Clinical” track will fund the identification, validation, and/or development of new pharmacological and non-pharmacological interventions through preclinical development, from early detection to characterization and preclinical testing.
Funding for projects will depend on their novelty, development status, and priority.
Requirements:
Applicants must be basic or clinical researchers affiliated with:
- Biotechnology/pharmaceutical companies or other public or private for-profit organizations.
- Nonprofit organizations, whether public or private, such as universities, hospitals, or research centers.
*Only applications from industry and from partnerships between academia and industry will be accepted.
How to apply
Applications must be submitted through the application portal and attaching the following documentation:
Submission deadline.
The application process consists of two phases, with three deadlines set for the review of proposals in 2025:
- January 12, 2025
- March 27, 2025
- Applications submitted by June 5, 2025, will be processed in August 2025.